Literature DB >> 32568153

Documenting disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Richard Podell1, Mary E Dimmock2, Barbara B Comerford3.   

Abstract

BACKGROUND: According to the 2015 National Academy of Medicine report, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) "is a serious, chronic, complex, and systemic disease that frequently and dramatically limits the activities of affected patients." ME/CFS affects between 1 and 2.5 million Americans, leaving as many as 75% unable to work due to physical, cognitive and functional impairment. Unfortunately, many doctors and lawyers lack the knowledge of how to properly document an ME/CFS disability claim, leaving patients unable to access disability benefits.
OBJECTIVE: The goal of this article is to summarize the approaches used by experienced clinicians and lawyers in successful ME/CFS disability claims.
METHODS: The authors reviewed the types of US disability insurance programs and the evidence commonly required by these programs to demonstrate ME/CFS disability.
RESULTS: This article summarizes the range of methods used in successful US disability claims, which include documentation of the functional impact of post-exertional malaise and the use of methods that provide objective evidence of impairment.
CONCLUSIONS: Medical providers and lawyers can use these tested methods to obtain disability benefits for people with ME/CFS. Physical therapists, occupational therapists, and other specialists play an important role in providing objective evidence for ME/CFS disability claims.

Entities:  

Keywords:  Chronic Fatigue Syndrome; ME/CFS; Myalgic Encephalomyelitis; disability; functional impairment

Mesh:

Year:  2020        PMID: 32568153     DOI: 10.3233/WOR-203178

Source DB:  PubMed          Journal:  Work        ISSN: 1051-9815


  1 in total

1.  Opportunities to Improve Long COVID Care: Implications from Semi-structured Interviews with Black Patients.

Authors:  Rachel S Bergmans; Keiyana Chambers-Peeple; Deena Aboul-Hassan; Samantha Dell'Imperio; Allie Martin; Riley Wegryn-Jones; Lillian Z Xiao; Christine Yu; David A Williams; Daniel J Clauw; Melissa DeJonckheere
Journal:  Patient       Date:  2022-07-30       Impact factor: 3.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.